Edition:
United States

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

7.40USD
22 Sep 2017
Change (% chg)

$0.05 (+0.68%)
Prev Close
$7.35
Open
$7.35
Day's High
$7.43
Day's Low
$7.35
Volume
13,130
Avg. Vol
52,491
52-wk High
$9.60
52-wk Low
$3.90

Latest Key Developments (Source: Significant Developments)

Kindred Biosciences Q2 loss per share $0.29
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Kindred Biosciences Inc :Kindred Biosciences announces second quarter 2017 financial results.Q2 loss per share $0.29.Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Kindred Biosciences - ‍for 2017 , reiterates its previous guidance for operating expenses to be in range of $30 million to $32 million, excluding items​.  Full Article

Kindred Biosciences says board appointed Wendy Wee as CFO - SEC Filing
Friday, 28 Jul 2017 05:19pm EDT 

July 28 (Reuters) - Kindred Biosciences Inc :Kindred Biosciences Inc - On July 24, 2017, board of directors of co appointed Wendy Wee as CFO of company, effective July 28, 2017 - SEC Filing.Kindred Biosciences Inc - As of July 28, 2017, date of Wee's appointment as CFO, Richard Chin no longer serves as interim chief financial officer.  Full Article

KindredBio announces pricing of public offering
Wednesday, 12 Jul 2017 08:40am EDT 

July 12 (Reuters) - Kindred Biosciences Inc :KindredBio announces pricing of public offering.Says public offering of 3.00 million common shares priced at $7.50 per share.  Full Article

Kindredbio announces proposed public offering of common stock
Tuesday, 11 Jul 2017 04:10pm EDT 

July 11 (Reuters) - Kindred Biosciences Inc :Kindredbio announces proposed public offering of common stock.Kindred Biosciences-intends to use net proceeds for expansion of commercial infrastructure in anticipation of future product approvals, launches.Kindred Biosciences Inc - also intends to use net proceeds for expansion of its manufacturing capacity, development of its therapeutic candidates.  Full Article

Kindred Biosciences reports acquisition of Kansas manufacturing plant
Monday, 26 Jun 2017 07:30am EDT 

June 26 (Reuters) - Kindred Biosciences Inc ::Kindred Biosciences announces acquisition of Kansas manufacturing plant and execution of commercial manufacturing agreement for Zimeta.Kindred Biosciences announces acquisition of Kansas manufacturing plant and execution of commercial manufacturing agreement for Zimeta.Kindred Biosciences Inc - total purchase price was $3.75 million.Kindred Biosciences Inc says ‍also announced execution of a commercial manufacturing agreement with Corden Pharma S.P.A for manufacture of Zimeta​.Kindred Biosciences - agreement with Corden Pharma is for initial 3-year term, permits for automatic renewal period of 2-years upon conclusion of initial term.Says ‍company also announced completion of its ATM financing​.  Full Article

Kindred Biosciences announces Q1 loss per share $0.30
Wednesday, 3 May 2017 04:01pm EDT 

May 3 (Reuters) - Kindred Biosciences Inc :Kindred Biosciences announces first quarter 2017 financial results.Q1 loss per share $0.30.Kindred Biosciences Inc says for 2017 calendar year, company reiterates its previous guidance for operating expenses to be in range of $30 million to $32 million.  Full Article

Kindred Biosciences Q4 loss per share $0.29
Wednesday, 1 Mar 2017 04:01pm EST 

Kindred Biosciences Inc : Kindred biosciences announces fourth quarter and year-end 2016 financial results . Q4 loss per share $0.29 .Q4 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.  Full Article

Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz
Monday, 6 Feb 2017 09:00am EST 

Kindred Biosciences Inc : Kindred biosciences receives early approval of effectiveness technical section from fda for mirataz™ new animal drug application . Kindred biosciences inc - has received a technical section complete letter for effectiveness from u.s. Food and drug administration . Kindred biosciences inc says expect approval of mirataz in second half of 2017 assuming no unforeseen delays in review process .Kindred biosciences inc - basis for complete letter was a multicenter, randomized, double-blind, placebo-controlled pivotal field study.  Full Article

Kindred Biosciences gets approval from FDA for new animal drug application
Tuesday, 4 Oct 2016 04:01pm EDT 

Kindred Biosciences Inc : Kindred Biosciences receives approval of effectiveness technical section from fda for zimeta new animal drug application . Kindredbio is in process of responding to first round of review by fda on safety technical section .Kindred Biosciences Inc says expects approval of Zimeta in first half of 2017 if FDA review process is rapid.  Full Article

Kindred Biosciences submits final major NADA technical section for Safety for Mirataz to FDA
Friday, 30 Sep 2016 09:01am EDT 

Kindred Biosciences Inc : Kindred Biosciences submits final major New Animal Drug Application technical section for Safety for Mirataz to FDA and launches KindredBio Equine website .In target animal safety study, Mirataz was generally well-tolerated and no significant safety concerns were identified.  Full Article

BRIEF-Kindred Biosciences Q2 loss per share $0.29

* Kindred Biosciences announces second quarter 2017 financial results